Patents by Inventor Michael Edward Mertzman

Michael Edward Mertzman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SUBSTITUTED HETEROCYCLIC COMPOUNDS
    Publication number: 20240124421
    Abstract: There are disclosed compounds of the following formula I: or a stereoisomer or pharmaceutically acceptable salt thereof, wherein all substituents are as defined herein, which are useful in the modulation of IL-12, IL-23 and/or IFN?, by acting on Tyk-2 to cause signal transduction inhibition. The compounds of the invention may be useful for treating neurodegenerative diseases or disorders.
    Type: Application
    Filed: December 14, 2023
    Publication date: April 18, 2024
    Inventors: Steven H. Spergel, Ryan M. Moslin, Michael Edward Mertzman
  • Substituted heterocyclic compounds
    Patent number: 11884650
    Abstract: There are disclosed compounds of the following formula I: or a stereoisomer or pharmaceutically acceptable salt thereof, wherein all substituents are as defined herein, which are useful in the modulation of IL-12, IL-23 and/or IFN?, by acting on Tyk-2 to cause signal transduction inhibition. The compounds of the invention may be useful for treating neurodegenerative diseases or disorders.
    Type: Grant
    Filed: May 13, 2022
    Date of Patent: January 30, 2024
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Steven H. Spergel, Ryan M. Moslin, Michael Edward Mertzman
  • Substituted heterocyclic compounds
    Patent number: 11866414
    Abstract: There are disclosed compounds of the following formula I: or a stereoisomer or pharmaceutically acceptable salt thereof, wherein all substituents are as defined herein, which are useful in the modulation of IL-12, IL-23 and/or IFN?, by acting on Tyk-2 to cause signal transduction inhibition. The compounds of the invention may be useful for treating neurodegenerative diseases or disorders.
    Type: Grant
    Filed: May 13, 2022
    Date of Patent: January 9, 2024
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Steven H. Spergel, Ryan M. Moslin, Michael Edward Mertzman, Zili Xiao
  • SUBSTITUTED HETEROCYCLIC COMPOUNDS
    Publication number: 20220411384
    Abstract: There are disclosed compounds of the following formula I: or a stereoisomer or pharmaceutically acceptable salt thereof, wherein all substituents are as defined herein, which are useful in the modulation of IL-12, IL-23 and/or IFN?, by acting on Tyk-2 to cause signal transduction inhibition. The compounds of the invention may be useful for treating neurodegenerative diseases or disorders.
    Type: Application
    Filed: May 13, 2022
    Publication date: December 29, 2022
    Inventors: Steven H. Spergel, Ryan M. Moslin, Michael Edward Mertzman, Joseph A. Tino, Shoshana L. Posy, Sirish Kaushik Lakkaraju, Zili Xiao, James Kempson
  • SUBSTITUTED HETEROCYCLIC COMPOUNDS
    Publication number: 20220388987
    Abstract: There are disclosed compounds of the following formula I: or a stereoisomer or pharmaceutically acceptable salt thereof, wherein all substituents are as defined herein, which are useful in the modulation of IL-12, IL-23 and/or IFN?, by acting on Tyk-2 to cause signal transduction inhibition. The compounds of the invention may be useful for treating neurodegenerative diseases or disorders.
    Type: Application
    Filed: May 13, 2022
    Publication date: December 8, 2022
    Inventors: Steven H. Spergel, Ryan M. Moslin, Michael Edward Mertzman